Progress in Protein Therapeutics

Dear Colleagues,

Protein therapeutics play a pivotal role in precision medicine by developing highly targeted treatments customized to the biomolecular profiles and specific disease characteristics of individual patients. By capitalizing on the unique attributes of proteins, such as their capacity for selective binding to particular targets within the body, protein therapeutics can finely regulate disease pathways while mitigating off-target effects. This precision empowers healthcare providers to administer personalized treatments that optimize efficacy and minimize adverse reactions. Through advancements in molecular medicine, protein therapeutics are increasingly being engineered to target specific molecular aberrations underlying diverse complex diseases. In recent years, strides have been made in next-generation monoclonal antibodies, engineering methods for enhanced pharmacokinetics, multifunctional fusion proteins, and innovative delivery methods within the space of protein therapeutics. Ongoing efforts are currently addressing challenges such as immunogenicity, manufacturing complexity, targeting intracellular proteins, and off-target effects to develop more efficacious and precision-medicine-based protein therapeutics.

We are pleased to invite you to contribute original research articles with reference to (but not limited to) new advancements in the design, production, and applications of protein therapeutics and using protein therapeutics for precision medicine practices. We also especially welcome critical review manuscripts with a vision perspective, setting the stage for future research.

Dr. Iman Tavassoly
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biologics
• monoclonal antibodies
• recombinant proteins
• therapeutic peptides
• protein engineering
• protein therapeutics